EU Committee Backs BioArctic's Exidavnemab for Multiple System Atrophy in EU

Published on 22/05/2025 at 20:10

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about BioArctic AB

Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	17/06	FW
BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	13/06	MT
BioArctic to Initiate Next Cohorts in Exidavnemab Phase 2a Study After Positive Safety Review	13/06	CI
Bioarctic initiates next step in Exist study following positive safety evaluation	13/06	FW
Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review	13/06	RE
BioArctic AB - Analyst/Investor Day	03/06
Bioarctic will present its ambitions for 2030 during its Capital Markets Day.	02/06	FW
Goldman Sachs lowers target price for Bioarctic to SEK 237 (267), reiterates buy recommendation - BN	02/06	FW
BioArctic AB, Q1 2025 Earnings Call, May 21, 2025	23/05
EU Committee Backs BioArctic's Exidavnemab for Multiple System Atrophy in EU	22/05	MT
Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU	22/05	RE
Bioarctic receives positive opinion in the EU for orphan drug designation for exidavnemab	22/05	FW
EMA Committee recommends orphan drug designation for Bioarctics' exidavnemab for multiple system atrophy (R)	22/05	FW
EMA recommends safety classification of Bioarctics' exidavnemab for multiple system atrophy	22/05	FW
Bioarctic AB Announces That the European Medicines Agency Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation to Exidavnemab for the Treatment of Multiple System Atrophy	22/05	CI
Stockholm Bullets - Cinclus Pharma surges on commercialization agreement	22/05	FW
Eli Lilly's Alzheimer's treatment approved in Australia	22/05	FW
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	21/05	CI
Bioarctic increases sales and operating profit (update)	21/05	FW
Bioarctic increases sales and operating profit	21/05	FW
Recovery on the Stockholm Stock Exchange, OMXS30 index rose 0.2 percent.	19/05	FW
Bioarctic celebrates FDA announcement on blood test, more people will be able to receive treatment - Di	19/05	FW
Stockholm Bullets - Bioarctic rises on FDA announcement regarding blood test	19/05	FW
FDA approves first blood test for detecting Alzheimer's	19/05	FW
Stockholm Bullets - Nibe declines on report	15/05	FW